Sickle-cell Anemia Therapeutics Market in the US 2015-2019
|出版商||TechNavio (Infiniti Research Ltd.)||商品編碼||322845|
|出版日期||內容資訊||英文 51 Pages
|美國的鐮狀細胞貧血治療市場 Sickle-cell Anemia Therapeutics Market in the US 2015-2019|
|出版日期: 2015年01月07日||內容資訊: 英文 51 Pages||
Sickle-cell anemia is a disease characterized by the presence of sickle-shaped erythrocytes. While normal erythrocytes have a life span of 120 days, sickle-shaped erythrocytes die within 10 to 20 days. The bone marrow is unable to compensate for the excessive loss of erythrocytes, thereby leading to anemia. It is an inheritable disorder passed on across generations. The prevalence of the sickle-cell gene varies between different ethnic groups and geographical locations.
TechNavio's analysts forecast the Sickle-cell Anemia Therapeutics market in the US to grow at a CAGR of 17.10 percent over the period 2014-2019.
This report covers the present scenario and the growth prospects of the Sickle-cell Anemia Therapeutics market in the US for the period 2015-2019. To calculate the market size, the report considers the revenue generated through the sales of the US FDA-approved drugs used for the treatment of sickle-cell anemia.
TechNavio's report, Sickle-cell Anemia Therapeutics Market in US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the Sickle-cell Anemia Therapeutics market landscape in the US and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.